Brandes Investment Partners LP Acquires 216,411 Shares of Pfizer Inc. $PFE

Brandes Investment Partners LP lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,629,182 shares of the biopharmaceutical company’s stock after acquiring an additional 216,411 shares during the period. Pfizer makes up 1.6% of Brandes Investment Partners LP’s holdings, making the stock its 15th biggest holding. Brandes Investment Partners LP’s holdings in Pfizer were worth $214,867,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Triad Wealth Partners LLC increased its position in shares of Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after acquiring an additional 386 shares in the last quarter. ETF Store Inc. increased its position in shares of Pfizer by 3.8% during the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after acquiring an additional 396 shares in the last quarter. Mattern Wealth Management LLC increased its position in shares of Pfizer by 4.6% during the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after acquiring an additional 400 shares in the last quarter. Pines Wealth Management LLC increased its position in shares of Pfizer by 4.4% during the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 400 shares in the last quarter. Finally, Pathway Financial Advisers LLC grew its position in Pfizer by 0.9% in the 4th quarter. Pathway Financial Advisers LLC now owns 46,380 shares of the biopharmaceutical company’s stock worth $1,155,000 after purchasing an additional 403 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on PFE shares. Wolfe Research reaffirmed an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research report on Thursday, February 12th. HSBC upped their price objective on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Barclays started coverage on shares of Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective for the company. Finally, CICC Research began coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $28.82.

Pfizer Stock Performance

Shares of PFE stock opened at $25.67 on Wednesday. The stock has a market capitalization of $146.28 billion, a P/E ratio of 19.59 and a beta of 0.34. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The firm’s 50 day moving average is $26.56 and its 200 day moving average is $26.31. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio is presently 131.30%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved an expanded indication for HYMPAVZI, broadening use to more hemophilia A/B patients and children, which could increase future sales. Article Title
• Positive Sentiment: Pfizer’s obesity pipeline remains in focus after phase 2b data showed about 16% weight loss, reinforcing optimism that the company may build a meaningful next-generation growth franchise. Article Title
• Neutral Sentiment: BMO Capital kept its Buy rating on Pfizer, adding support for the stock but not changing the core story by itself. Article Title
• Neutral Sentiment: Multiple articles highlighted Pfizer’s obesity strategy and its effort to find new growth after the COVID windfall faded, which is encouraging but still early-stage. Article Title
• Negative Sentiment: Broader commentary on patent cliffs and rising competition in obesity drugs underscores the pressure Pfizer faces to replace lost revenue and prove its pipeline can deliver. Article Title

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.